A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE VS OTHER THERAPUETIC OPTIONS IN THE TREATEMENT OF RHEUMATOID ARTHRITIS

Author(s)

Przemyslaw Rys, MD, Vice president1, Kariolina Kucia, student, Researcher1, Oskar Pankiewicz, MSC, Researcher1, Agnieszka Rogoz, MSC, Researcher1, Joanna Lis, PhD, MBA, Menager2, Agnieszka Nadzieja-Koziol, Student, Researcher1, Anna Gurda-Duda, PhD, Researcher11HTA Consulting, Krakow, Poland; 2 Sanofi-Aventis sp. z o.o, Warszawa, Poland

OBJECTIVES: The objective of this study was to compare efficacy and safety of leflunomide with biological antirheumatic drugs (adalimumab, etanercept, infliximab, rituximab, anakinra) in active rheumatoid arthritis.  METHODS: Comparison was based on systematic review, carried out according to guidelines published by the Cochrane Collaboration and Agency for Technology Assessment in Poland. The most important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two reviewers independently selected trials, assessed trial quality and extracted data. No head to head trials were identified so indirect comparison using Bucher’s method was performed. RESULTS: The results of 33 randomized controlled trials were included in indirect comparison. Leflunomide was shown to have better ACR20 response than anakinra (RR=1.44 [1.14; 1.81]) but no significant differences in ACR response were found in comparisons with other drugs. Comparisons of HAQ disability scores indicate than leflunomide reduces disability better than adalimumab (WMD=-0.15; [-0.29; -0.01]), infliximab (WMD=-0.35 [-0.50; -0.20]), anakinra (WMD=-0.47 [-0.69; -0.25]), rituximab (WMD=-0.38 [-0.59; -0.17]), but not etanercept (WMD=-0.18 [-0.37; 0.01]). Radiographic improvement was better in comparison with anakinra (WMD=-2.99 [-5.82; -0.16]) and rituximab (WMD=-4.05 [-6.67; -1.43]) whereas worse in comparison with adalimumab (WMD=2.67 [0.87; 4.47]), etanercept (WMD=1.75 [0.01;3.49]) and infliximab (WMD=2.06 [0.42; 3.70]). Leflunomid significantly increases the risk of treatment discontinuation due to the adverse events in comparison with etanercept (RR=3.50 [1.55; 7.88]). No significant differences in safety outcomes were noted between leflunomid and other drugs. CONCLUSIONS: Indirect comparisons indicate similar efficacy of leflunomid, adalimumab, etanercept, infliximab or rituximab. Leflunomide seems to be more effective than anakinra. Safety profile of leflunomide is worse in comparison with etanercept, whereas in comparison with other analyzed drugs no differences were found.

Conference/Value in Health Info

2008-11, ISPOR Europe 2008, Athens, Greece

Value in Health, Vol. 11, No. 6 (November 2008)

Code

PMS3

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×